439 related articles for article (PubMed ID: 36704045)
21. Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy.
Goleva E; Lyubchenko T; Kraehenbuehl L; Lacouture ME; Leung DYM; Kern JA
Ann Allergy Asthma Immunol; 2021 Jun; 126(6):630-638. PubMed ID: 33716146
[TBL] [Abstract][Full Text] [Related]
22. Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer.
Gaynor N; Crown J; Collins DM
Semin Cancer Biol; 2022 Feb; 79():44-57. PubMed ID: 32623044
[TBL] [Abstract][Full Text] [Related]
23. Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma.
Mei Z; Huang J; Qiao B; Lam AK
Int J Oral Sci; 2020 May; 12(1):16. PubMed ID: 32461587
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade.
Genova C; Dellepiane C; Carrega P; Sommariva S; Ferlazzo G; Pronzato P; Gangemi R; Filaci G; Coco S; Croce M
Front Immunol; 2021; 12():799455. PubMed ID: 35069581
[TBL] [Abstract][Full Text] [Related]
25. The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer.
Alemohammad H; Najafzadeh B; Asadzadeh Z; Baghbanzadeh A; Ghorbaninezhad F; Najafzadeh A; Safarpour H; Bernardini R; Brunetti O; Sonnessa M; Fasano R; Silvestris N; Baradaran B
Biomed Pharmacother; 2022 Feb; 146():112516. PubMed ID: 34906767
[TBL] [Abstract][Full Text] [Related]
26. Immune Checkpoint Molecules-Inherited Variations as Markers for Cancer Risk.
Wagner M; Jasek M; Karabon L
Front Immunol; 2020; 11():606721. PubMed ID: 33519815
[TBL] [Abstract][Full Text] [Related]
27. Immune checkpoint modulators in early clinical development for the treatment of type 1 diabetes.
Maddaloni E; Amendolara R; Balena A; Latino A; Sessa RL; Buzzetti R
Expert Opin Investig Drugs; 2024 Apr; 33(4):303-318. PubMed ID: 38427915
[TBL] [Abstract][Full Text] [Related]
28. Pivotal role of PD-1/PD-L1 immune checkpoints in immune escape and cancer progression: Their interplay with platelets and FOXP3+Tregs related molecules, clinical implications and combinational potential with phytochemicals.
Lee DY; Im E; Yoon D; Lee YS; Kim GS; Kim D; Kim SH
Semin Cancer Biol; 2022 Nov; 86(Pt 3):1033-1057. PubMed ID: 33301862
[TBL] [Abstract][Full Text] [Related]
29. Type 1 diabetes induced by immune checkpoint inhibitors.
Zhang R; Cai XL; Liu L; Han XY; Ji LN
Chin Med J (Engl); 2020 Nov; 133(21):2595-2598. PubMed ID: 32842016
[TBL] [Abstract][Full Text] [Related]
30. The multifaceted nature of diabetes mellitus induced by checkpoint inhibitors.
Marchand L; Disse E; Dalle S; Reffet S; Vouillarmet J; Fabien N; Thivolet C; Cugnet-Anceau C
Acta Diabetol; 2019 Dec; 56(12):1239-1245. PubMed ID: 31423559
[TBL] [Abstract][Full Text] [Related]
31. Role of Epigenetic Modifications in Inhibitory Immune Checkpoints in Cancer Development and Progression.
Saleh R; Toor SM; Sasidharan Nair V; Elkord E
Front Immunol; 2020; 11():1469. PubMed ID: 32760400
[TBL] [Abstract][Full Text] [Related]
32. The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy.
Setordzi P; Chang X; Liu Z; Wu Y; Zuo D
Eur J Pharmacol; 2021 Mar; 895():173867. PubMed ID: 33460617
[TBL] [Abstract][Full Text] [Related]
33. NK Cell-Based Immune Checkpoint Inhibition.
Khan M; Arooj S; Wang H
Front Immunol; 2020; 11():167. PubMed ID: 32117298
[TBL] [Abstract][Full Text] [Related]
34. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer.
Zhang H; Dai Z; Wu W; Wang Z; Zhang N; Zhang L; Zeng WJ; Liu Z; Cheng Q
J Exp Clin Cancer Res; 2021 Jun; 40(1):184. PubMed ID: 34088360
[TBL] [Abstract][Full Text] [Related]
35. Targeting Immune Cell Checkpoints during Sepsis.
Patil NK; Guo Y; Luan L; Sherwood ER
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29135922
[TBL] [Abstract][Full Text] [Related]
36. Immune checkpoints and their inhibitors: Reappraisal of a novel diagnostic and therapeutic dimension in the urologic malignancies.
Sardana R; Mishra SK; Williamson SR; Mohanty A; Mohanty SK
Semin Oncol; 2020 Dec; 47(6):367-379. PubMed ID: 33160642
[TBL] [Abstract][Full Text] [Related]
37. Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma.
El Halabi L; Adam J; Gravelle P; Marty V; Danu A; Lazarovici J; Ribrag V; Bosq J; Camara-Clayette V; Laurent C; Ghez D
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):257-266.e3. PubMed ID: 33277223
[TBL] [Abstract][Full Text] [Related]
38. Targeting Histone 3 Variants Epigenetic Landscape and Inhibitory Immune Checkpoints: An Option for Paediatric Brain Tumours Therapy.
Meenakshi S; Maharana KC; Nama L; Vadla UK; Dhingra S; Ravichandiran V; Murti K; Kumar N
Curr Neuropharmacol; 2024; 22(7):1248-1270. PubMed ID: 37605389
[TBL] [Abstract][Full Text] [Related]
39. Immune checkpoint inhibitors as potential therapy for reverting T-cell exhaustion and reverting HIV latency in people living with HIV.
Benito JM; Restrepo C; García-Foncillas J; Rallón N
Front Immunol; 2023; 14():1270881. PubMed ID: 38130714
[TBL] [Abstract][Full Text] [Related]
40. Cardiotoxicity of immune checkpoint inhibitors.
Varricchi G; Galdiero MR; Marone G; Criscuolo G; Triassi M; Bonaduce D; Marone G; Tocchetti CG
ESMO Open; 2017; 2(4):e000247. PubMed ID: 29104763
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]